2025
Lung adenocarcinoma-derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines
Kratzmeier C, Taheri M, Mei Z, Lim I, Khalil M, Carter-Cooper B, Fanaroff R, Ong C, Schneider E, Chang S, Leyder E, Li D, Luzina I, Banerjee A, Krupnick A. Lung adenocarcinoma-derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines. Journal Of Clinical Investigation 2025, 135: e191070. PMID: 40553564, PMCID: PMC12404755, DOI: 10.1172/jci191070.Peer-Reviewed Original ResearchCD8+ T cellsIFN-gCCR5 chemokinesT cellsCD4+Foxp3+ T regulatory cellsCD8+ T-cell productionCancer cellsHuman lung cancer patientsLevels of IFN-gT regulatory cellsMurine lung adenocarcinomaLung adenocarcinoma modelLung cancer patientsMechanisms of immunoregulationCell line modelsLung cancer cellsTumor bedAdenocarcinoma modelTh1 cytokinesTumor microenvironmentImmunological environmentImmunoregulatory pathwaysCarcinogen-inducedTumor growthLung cancerSpatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures
Mebane R, Noel T, Ing N, Gouin K, Shah A, Zitser D, Martinez A, Gupta G, Demaria S, Galluzzi L, Ho A, McArthur H, Shiao S, Knott S. Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures. IScience 2025, 28: 112808. PMID: 40599321, PMCID: PMC12209978, DOI: 10.1016/j.isci.2025.112808.Peer-Reviewed Original ResearchTertiary lymphoid structuresLymphoid structuresRadiation therapyImmunotherapy responseImmune checkpoint blockade responseTriple negative breast cancerCancer immunotherapy responseNegative breast cancerCancer cell removalTumor bedBlockade responseMalignant cellsBreast tumorsImmune activationMacrophage infiltrationPembrolizumabBreast cancerLongitudinal biopsiesSpatial transcriptomic analysisTumorTherapyCancerInfiltrationCell removalImmunotherapy
2023
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
Lopez De Rodas M, Wang Y, Peng G, Gu J, Mino-Kenudson M, Riess J, Velcheti V, Hellmann M, Gainor J, Zhao H, Schalper K. Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer. Clinical Cancer Research 2023, 30: 998-1008. PMID: 38127300, PMCID: PMC10922461, DOI: 10.1158/1078-0432.ccr-23-2457.Peer-Reviewed Original ResearchNon-small cell lung cancerTIL subsetsCell lung cancerImmune evasion mechanismsSubset of casesLymphocyte infiltration patternsPathology-based approachStrong biomarker potentialTIL markersNSCLC patientsImmunotherapy outcomesLymphocyte patternsLung cancerTumor bedWorse outcomesClinical significanceMost tumorsEvasion mechanismsStromal tissueTumor samplesMultiplexed immunofluorescenceBiomarker potentialTumorsInfiltration patternsImmunotherapyInternational Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy
Dacic S, Travis W, Redman M, Saqi A, Cooper W, Borczuk A, Chung J, Glass C, Lopez J, Roden A, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne M, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee J, Berezowska S, Chou T, Kerr K, Nicholson A, Poleri C, Schalper K, Tsao M, Carbone D, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn P, Kris M, Belani C, Kelly K, Wistuba I, Committee I. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal Of Thoracic Oncology 2023, 18: 1290-1302. PMID: 37702631, DOI: 10.1016/j.jtho.2023.07.017.Peer-Reviewed Original ResearchConceptsPathologic responseViable tumorNeoadjuvant therapyLung cancerClinical trialsInter-rater agreementNeoadjuvant immune checkpoint inhibitorsClinical trial end pointsResected Lung CancerImmune checkpoint inhibitorsTrial end pointsInvasive mucinous adenocarcinomaResidual viable tumorTumor bed areaEosin-stained slidesLung cancer studiesCheckpoint inhibitorsNeoadjuvant treatmentMucinous adenocarcinomaPathologic evaluationStromal inflammationPulmonary pathologistsTumor bedLung tumorsCommon reason
2018
Oncolytic virus immunotherapy: future prospects for oncology
Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. Journal For ImmunoTherapy Of Cancer 2018, 6: 140. PMID: 30514385, PMCID: PMC6280382, DOI: 10.1186/s40425-018-0458-z.Peer-Reviewed Original ResearchConceptsOncolytic virusesSevere immune-related adverse eventsImmune-related adverse eventsAnti-tumor immune responseEarly-stage clinical trialsImmune checkpoint inhibitorsSerious adverse effectsOncolytic viral therapyLimited therapeutic responseAnti-cancer treatmentLocal target cellsCheckpoint inhibitorsSalvage therapyTolerability profileCytotoxic chemotherapyAdverse eventsImmune dysregulationOncologic careTherapeutic optionsTumor bedSuch therapyTherapeutic responseClinical trialsNovel therapiesViral therapy
2016
PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016, 105: 136-144. PMID: 27521616, PMCID: PMC5072177, DOI: 10.1016/j.biomaterials.2016.07.037.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryGlioblastoma multiformeChemotherapeutic drugsFirst-line treatmentExtracranial solid tumorTumor-bearing animalsSurvival of animalsBrain extracellular spaceLine treatmentTumor bedIntracranial tumorsOrthotopic modelTreatment resistanceSolid tumorsGBM treatmentTherapeutic efficacyNew treatmentsTumor tissueHealthy animalsGBM prognosisFree gemcitabineMR contrast agentsNucleoside analoguesDrugsGemcitabineA mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley M, Cardona D, Lazarides A, Spasojevic I, Ferrer J, Cahill J, Lee C, Snuderl M, Blazer D, Hwang E, Greenup R, Mosca P, Mito J, Cuneo K, Larrier N, O'Reilly E, Riedel R, Eward W, Strasfeld D, Fukumura D, Jain R, Lee W, Griffith L, Bawendi M, Kirsch D, Brigman B. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine 2016, 8: 320ra4. PMID: 26738797, PMCID: PMC4794335, DOI: 10.1126/scitranslmed.aad0293.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasLocal recurrenceTumor bedClinical trialsIntravenous injectionPhase 1 clinical trialHuman phase 1 clinical trialCo-clinical studiesMicroscopic residual cancerPositive surgical marginsFuture clinical trialsCo-clinical trialsRates of reexcisionAdjuvant therapyResidual cancerSurgical marginsTreatment failureTissue sarcomasBreast cancerCommon causeIntraoperative detectionMouse modelPharmacokinetic profileSolid tumorsCancer
2012
Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. Journal Of NeuroInterventional Surgery 2012, 5: e42. PMID: 23188789, DOI: 10.1136/neurintsurg-2012-010508.rep.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingCerebral AngiographyContrast MediaDrug Delivery SystemsFollow-Up StudiesGadoliniumHumansInfantInjections, Intra-ArterialIntraoperative PeriodMagnetic Resonance AngiographyMaleMelphalanRetinal ArteryRetinal DetachmentRetinal NeoplasmsRetinoblastomaTreatment OutcomeVisual AcuityVerification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium
Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. BMJ Case Reports 2012, 2012: bcr2012010508. PMID: 23162039, PMCID: PMC4545047, DOI: 10.1136/bcr-2012-010508.Peer-Reviewed Original Research
2011
ACR Appropriateness Criteria® Ductal Carcinoma in Situ
Moran MS, Bai HX, Harris EE, Arthur DW, Bailey L, Bellon JR, Carey L, Goyal S, Halyard MY, Horst KC, MacDonald SM, Haffty BG. ACR Appropriateness Criteria® Ductal Carcinoma in Situ. The Breast Journal 2011, 18: 8-15. PMID: 22107336, DOI: 10.1111/j.1524-4741.2011.01197.x.Peer-Reviewed Original ResearchConceptsWhole breast radiationDuctal carcinomaAppropriateness CriteriaMultiple phase III studiesAppropriateness of imagingPhase III studyACR Appropriateness CriteriaExpert panelRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelOmission of radiationPartial breast radiationSpecific clinical conditionsCurrent medical literatureNon-invasive tumorsInvasive relapseBreast radiationLimited diseaseIII studyPeer-reviewed journalsLocal recurrenceAppropriate patientsTumor bedClinical guidelinesSurgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy.
Lannin D, Grube B, Killelea B, Horowitz N, Harris L. Surgical and oncologic outcomes in patients with breast cancer undergoing tattooing prior to neoadjuvant chemotherapy. Journal Of Clinical Oncology 2011, 29: 100-100. DOI: 10.1200/jco.2011.29.27_suppl.100.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyLocal recurrenceOncologic outcomesBreast cancerProspective breast cancer databaseBreast tissueBreast local recurrenceBreast preservation ratesEntire tumor bedSubsequent definitive therapyPartial response rateSeries of patientsLower ratesBreast preservationDefinitive therapyInitial surgeryChart reviewFurther surgeryMost patientsInitial lumpectomyPositive marginsSingle institutionTumor bedCancer DatabaseSurgical incision
2008
Preoperative Systemic Chemotherapy and Pathologic Assessment of Response
Pusztai L. Preoperative Systemic Chemotherapy and Pathologic Assessment of Response. Pathology & Oncology Research 2008, 14: 169-171. PMID: 18553157, DOI: 10.1007/s12253-008-9070-8.Peer-Reviewed Original ResearchConceptsPathologic complete responsePreoperative systemic chemotherapyResidual cancer burdenResidual diseaseNeoadjuvant treatmentSystemic chemotherapyAxillary nodal burdenNeoadjuvant clinical trialsRoutine therapeutic modalityAdvanced breast cancerPrimary tumor dimensionsTranslational research modelRoutine diagnostic practiceNodal burdenPathologic responseComplete responsePathologic assessmentPrognostic distinctionResistant diseaseCancer burdenAdverse outcomesTumor bedClinical trialsPathologic informationBreast cancer
2004
Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer: Imaging Considerations
Whitman G, Iyer R, Reeve C, Patel P, Phelps M, Pusztai L. Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer: Imaging Considerations. 2004, 7: 61-74. DOI: 10.1053/j.sembd.2005.01.005.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyMagnetic resonance imagingPositron emission tomographyBreast cancerAssessment of responseCurrent imaging techniquesPreoperative chemotherapyTumor bedClinical examinationChemotherapyFavorable responseResonance imagingEmission tomographyImaging considerationsCancerImaging techniquesMetal markersResponsePatientsSestamibiSonographyTherapyWomen
1993
Local recurrence versus new primary: Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting
Haffty B, Carter D, Flynn S, Fischer D, Brash D, Simons J, Ziegler A, Fischer J. Local recurrence versus new primary: Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. International Journal Of Radiation Oncology • Biology • Physics 1993, 27: 575-583. PMID: 8226151, DOI: 10.1016/0360-3016(93)90382-6.Peer-Reviewed Original ResearchConceptsNew primary tumorsBreast relapsePrimary tumorTrue recurrenceNew primaryConservative surgeryLocal recurrencePathological criteriaRadiation therapyOriginal tumorSurvival rateClinical pathological analysisSecond primary tumorsShorter median timeTrue local recurrenceSignificant prognostic implicationsDNA flow cytometryLocal relapseMedian timePrognostic implicationsResidual diseaseTumor bedPathological analysisRelapseTherapeutic implications
1985
Effects of fractionated irradiation of endocrine aspects of testicular function.
Shapiro E, Kinsella T, Makuch R, Fraass B, Glatstein E, Rosenberg S, Sherins R. Effects of fractionated irradiation of endocrine aspects of testicular function. Journal Of Clinical Oncology 1985, 3: 1232-9. PMID: 3928830, DOI: 10.1200/jco.1985.3.9.1232.Peer-Reviewed Original ResearchConceptsDose-dependent increaseGerm cell depletionCell depletionTesticular functionBaseline levelsFollicle-stimulating hormone valuesTotal testosterone valuesSerum FSH levelsMedian differenceLeydig cell dysfunctionSoft tissue sarcomasSerum follicle-stimulating hormone (FSH) valuesLeydig cell functionHigh-dose radiationLH changesTubule injuryFSH levelsOnly patientsSerum FSHLH concentrationsTesticular doseHormonal alterationsHormone valuesTumor bedRadiation injury
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply